Evidence map›Paper›PMID 26996755›Full record

ArticleJournal of molecular and cellular cardiology2016

Simulation of early calcific aortic valve disease in a 3D platform: A role for myofibroblast differentiation.

Jesper Hjortnaes, Claudia Goettsch, Joshua D Hutcheson, Gulden Camci-Unal, Lilian Lax, Katrin Scherer, Simon Body, Frederick J Schoen, Jolanda Kluin, Ali Khademhosseini and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 82 citations in OpenAlex.

  1. Review
  2. Article
  3. Optical Coherence Tomography in Acute Coronary Syndromes.Reviews in cardiovascular medicine · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Iranian journal of public health · 2024
    Article
  8. Article
  9. Models for calcific aortic valve disease in vivo and in vitro.Cell regeneration (London, England) · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jesper HjortnaesCenter of Excellence in Vascular Biology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Claudia GoettschCenter for Interdisciplinary Cardiovascular Sciences, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Joshua D HutchesonCenter for Interdisciplinary Cardiovascular Sciences, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Gulden Camci-UnalCenter for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Lilian LaxCenter of Excellence in Vascular Biology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Katrin SchererCenter of Excellence in Vascular Biology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Simon BodyDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Frederick J SchoenDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jolanda KluinDepartment of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Ali KhademhosseiniCenter for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. Electronic address: alik@bwh.harvard.edu.
Elena AikawaCenter of Excellence in Vascular Biology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Interdisciplinary Cardiovascular Sciences, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: eaikawa@partners.org.
Brigham and Women's Hospital · USHarvard University · USUniversity Medical Center Utrecht · NL

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
3D combinatorial microenvironments for effective cell based therapyR01HL099073 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, LIAO, RONGLIH · 2010 to 2013
$2.6M
Microfabricated Vascularized 3D Tissue Engineered ConstructsR01HL092836 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2008 to 2012
$2.4M
Genetic Etiology of Bicuspid Aortic Valve DiseaseR01HL114823 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BODY, SIMON C · 2012 to 2016
$2.1M
Aortic valve microcalcificationR01HL114805 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2012 to 2016
$2.1M
Microengineered environments for epithelial-mesenchymal interactions (SysCODE 7RL1DE019024 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2007 to 2011
$1.9M
Engineering Vascularized Bone Tissues By Microfabrication And ScaffoldingR01DE021468 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2011 to 2014
$1.8M
A Microfabrication Platform for Direct Printing Vascularized Functional Tissue CoR01EB012597 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN · 2010 to 2013
$1.4M
MICROFLUIDIC SYSTEM FOR SCREENING STEM CELL MICROENVIRONMENTSR01EB008392 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2009 to 2010
$820k
NHLBI NIH HHS R01 HL092836NHLBI NIH HHS R01 HL099073NHLBI NIH HHS R01 HL114805NHLBI NIH HHS R01 HL114823NIAMS NIH HHS R01 AR057837NIBIB NIH HHS R01 EB008392NIBIB NIH HHS R01 EB012597NIDCR NIH HHS R01 DE021468NIDCR NIH HHS RL1 DE019024
6 · The paper itself

Abstract

purposeCalcific aortic valve disease (CAVD) is the most prevalent valve disease in the Western world. Recent difficulty in translating experimental results on statins to beneficial clinical effects warrants the need for understanding the role of valvular interstitial cells (VICs) in CAVD. In two-dimensional culture conditions, VICs undergo spontaneous activation similar to pathological differentiation, which intrinsically limits the use of in vitro models to study CAVD. Here, we hypothesized that a three-dimensional (3D) culture system based on naturally derived extracellular matrix polymers, mimicking the microenvironment of native valve tissue, could serve as a physiologically relevant platform to study the osteogenic differentiation of VICs. PRINCIPAL

resultsAortic VICs loaded into 3D hydrogel constructs maintained a quiescent phenotype, similar to healthy human valves. In contrast, osteogenic environment induced an initial myofibroblast differentiation (hallmarked by increased alpha smooth muscle actin [α-SMA] expression), followed by an osteoblastic differentiation, characterized by elevated Runx2 expression, and subsequent calcific nodule formation recapitulating CAVD conditions. Silencing of α-SMA under osteogenic conditions diminished VIC osteoblast-like differentiation and calcification, indicating that a VIC myofibroblast-like phenotype may precede osteogenic differentiation in CAVD. MAJOR

conclusionsUsing a 3D hydrogel model, we simulated events that occur during early CAVD in vivo and provided a platform to investigate mechanisms of CAVD. Differentiation of valvular interstitial cells to myofibroblasts was a key mechanistic step in the process of early mineralization. This novel approach can provide important insight into valve pathobiology and serve as a promising tool for drug screening.

Indexed as

ActinsAnimalsAortic ValveAortic Valve StenosisApoptosisBiomarkersCalcinosisCell Culture TechniquesCell CycleCell DifferentiationCell SurvivalFluorescent Antibody TechniqueGene SilencingHumansHydrogelsIn Vitro TechniquesActinsBiomarkersHydrogelsAortic valve stenosisCalcific aortic valve diseaseHydrogelsTissue engineeringValvular interstitial cells

Identifiers

PMID26996755
PMCPMC4906202
OpenAlexW2300408236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.